Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 65.7%

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 58,200 shares, a decline of 65.7% from the February 13th total of 169,500 shares. Approximately 3.7% of the shares of the company are short sold. Based on an average trading volume of 2,650,000 shares, the short-interest ratio is presently 0.0 days.

NLS Pharmaceutics Stock Performance

Shares of NASDAQ NLSP traded up $0.05 during midday trading on Friday, hitting $1.58. 15,211 shares of the company’s stock were exchanged, compared to its average volume of 2,928,176. The stock’s 50 day moving average price is $1.98 and its 200-day moving average price is $2.42. NLS Pharmaceutics has a twelve month low of $1.47 and a twelve month high of $18.39.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).